The Trustees of Columbia University in the City of New York has been awarded a $402,911 Project Grant by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, titled "CELL-DRONES: ENGINEERED STEM CELL NANOVESICLES AS ALTERNATIVES TO EXOSOMES," aims to develop a scalable method to generate a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) through extrusion. The goal is to investigate the fabrication, characterization, and toxicity of these engineered "cell-drones" as well as evaluate their therapeutic effects on mouse and porcine models of cardiac ischemia/reperfusion injury. The project will also explore mechanisms underlying the therapeutic benefits of MSC NVs and explore ways to enhance their cargo for regenerative medicine applications. The award has a period of performance from Sep 1, 2024, to Aug 31, 2028.
Generated 3/4/25, 7:56 AM